Prostate Cancer Diagnostic Test

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals is a public, pre-revenue biotech company focused on improving outcomes in radiation oncology. Its core strategy involves developing proprietary small molecules that sensitize cancer cells to radiation while protecting healthy tissue, with a lead candidate, Ropidoxuridine, in Phase II trials. The company also leverages strategic academic collaborations, notably with Georgetown University, for drug discovery and is exploring diagnostic tests to personalize radiation therapy. Despite its innovative approach, Shuttle faces significant risks common to early-stage biotechs, including clinical trial execution, funding needs, and intense competition.

Therapeutic Areas